Macomics teams up with the Swiss cancer institute cancer institute to develop macrophage therapies

2024-06-19

交易

AACR会议

Macomics partnered with the Institute of Oncology Research (IOR) to test the former’s macrophage-targeted therapies in the latter’s mouse models of prostate cancer.

“Macrophages are key to multiple diseases of high unmet medical need, including as key mediators of solid tumour immunosuppression,” Macomics CEO Stephen Myatt said. “This collaboration enhances further our ability to explore and exploit macrophage biology for the development of novel therapeutic approaches.”

IOR’s mouse models of prostate cancer are specifically designed to feature the fundamental role of myeloid cells in tumour progression and are based on the institute’s “deep understanding of molecular mechanisms in cancer development,” said Andrea Alimonti, the director of IOR.

The partners will test and characterise Macomic’s macrophage-targeting drug candidates, which feature novel mechanisms of action.

Macrophage target discovery

Macomics’ pipeline of preclinical macrophage-targeting antibodies was built using its ENIGMAC platform, which combines patient datasets, macrophage cell models, and gene editing capabilities to discover new disease-specific macrophage targets.

The biotech shared early mechanistic and in vivo data for its lead cancer programme, a ligand independent-pan-LILRB antibody, at the American Association for Cancer Research meeting earlier this year. The results suggest MACO-355 can mediate macrophage reprogramming under immunosuppressive conditions.

Macomics is also working with the AIRC Institute of Molecular Oncology in Italy to characterise its macrophage-directed therapies with the research organisation’s ex vivo tumoroid models.

Separately, Ono Pharmaceutical has an exclusive option to license from Macomics an immuno-oncology candidate directed against a novel macrophage target.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构